87 FR 204 pgs. 64242-64243 - Agency Information Collection Activities: Submission for OMB Review; Comment Request
Type: NOTICEVolume: 87Number: 204Pages: 64242 - 64243
Pages: 64242, 64243FR document: [FR Doc. 2022-23054 Filed 10-21-22; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Substance Abuse and Mental Health Services Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under Office of Management and Budget (OMB) review, in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). To request a copy of these documents, email or call the SAMHSA Reports Clearance Officer at carlos.graham@samhsa.hhs.gov or (240) 276-0361.
Proposed Project: Program Evaluation for Prevention Contract (PEPC)-Strategic Prevention Framework for Prescription Drugs (SPF-Rx) Evaluation (OMB No. 0930-0377)-Revision
[top] The Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ) aims to complete a cross-site evaluation of SAMHSA's Strategic Prevention Framework for Prescription Drugs (SPF-Rx). SPF-Rx is designed to address nonmedical use of prescription drugs as well as opioid overdoses by raising awareness about the dangers of sharing medications and by working with pharmaceutical and medical communities on the risks of overprescribing. The SPF-Rx program aims to promote collaboration between
The SPF-Rx program's indicators of success are reductions in opioid overdoses, reductions in prescription drug misuse, and improved use of PDMP data. Data collected through the tools described in this statement will be used for the national cross-site evaluation of SAMHSA's SPF-Rx program. This package covers continued data collection through 2025. The Program Evaluation for Prevention Control (PEPC) team will systematically collect and maintain an Annual Reporting Tool (ART) and Grantee and Community Level Outcomes data modules submitted by SPF-Rx grantees through the online Data Management System (DMS).
SAMHSA is requesting approval for data collection for the SPF-Rx cross-site evaluation with the following instruments:
• Annual Reporting Tool (ART) -The ART is a survey instrument collected yearly to monitor state, tribal entity, and community-level performance, and to evaluate the effectiveness of the SPF-Rx program. This tool is completed by grantees and subrecipient community project directors and provides process data related to funding use and effectiveness, organizational capacity, collaboration with community partners, data infrastructure, planned intervention targets, intervention implementation, evaluation, contextual factors, training and technical assistance (T/TA) needs, and sustainability.
• Grantee-and Community-Level Outcomes Modules -These modules collect data on key SPF-Rx program outcomes, including opioid prescribing patterns and provider use of PDMP. Grantees will provide outcomes data at the grantee level for their state, tribal area, or jurisdiction, as well as at the community level for each of their subrecipient communities.
• Grantee-Level Interview -This qualitative interview will be administered at the end of the evaluation to obtain information from the grantee project directors on their programs, staffing, populations of focus, infrastructure, capacity, lessons learned, and collaboration.
| Instrument | Number of respondents | Responses per respondent | Total number of responses | Hours per response | Total burden hours |
|---|---|---|---|---|---|
| Annual Reporting Tool | a ?110 b ?21 | 1 1 | 110 21 | 4 3 | 440 63 |
| Grantee-Level PDMP Outcomes Module | b ?21 | 1 | 21 | 2.5 | 52.5 |
| Community-Level PDMP Outcomes Module | b ?21 | 5.2 | 110 | 1.25 | 137.5 |
| Grantee-Level Interview | b ?21 | 1 | 21 | 1.5 | 31.5 |
| FY2023 | 131 | 283 | 724.5 | ||
| Annual Reporting Tool | a ?110 b ?21 | 1 1 | 110 21 | 4 3 | 440 63 |
| Grantee-Level PDMP Outcomes Module | b ?21 | 1 | 21 | 2.5 | 52.5 |
| Community-Level PDMP Outcomes Module | b ?21 | 5.2 | 110 | 1.25 | 137.5 |
| Grantee-Level Interview | b ?0 | N/A | N/A | 1.5 | N/A |
| FY2024 | 131 | 283 | 693 | ||
| Annual Reporting Tool | a ?110 b ?21 | 1 1 | 110 21 | 4 3 | 440 63 |
| Grantee-Level PDMP Outcomes Module | b ?21 | 1 | 21 | 2.5 | 52.5 |
| Community-Level PDMP Outcomes Module | b ?21 | 5.2 | 110 | 1.25 | 137.5 |
| Grantee-Level Interview | b ?21 | 1 | 21 | 1.5 | 31.5 |
| FY2025 | 131 | 283 | 724.5 | ||
| a ?Community subrecipient respondent. | |||||
| b ?Grantee respondent. | |||||
Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain . Find this particular information collection by selecting "Currently under 30-day Review-Open for Public Comments" or by using the search function.
Carlos Graham,
Reports Clearance Officer.
[FR Doc. 2022-23054 Filed 10-21-22; 8:45 am]
BILLING CODE 4162-20-P